134575-17-0

Basic information

• Product Name: Carbamic acid, 3-azabicyclo[3.1.0]hex-6-yl-, 1,1-dimethylethyl ester,
• Synonyms: Carbamic acid, 3-azabicyclo[3.1.0]hex-6-yl-, 1,1-dimethylethyl ester,;TERT-BUTYL MESO-3-AZABICYCLO[3.1.0]HEX-6-YLCARBAMATE;(1à,5à,6à)-6-tert-Butoxycarbonylamino-3-azabicyclo[3.1.0]-hexane;exo-6-(Boc-amino)-3-azabicyclo[3.1.0]hexane;exo-6-(Boc-amino)-3-azabi...;tert-butyl (1R,5S)-3-azabicyclo[3.1.0]hexan-6-ylcarbamate;N-(1α,5α,6α)-3-Αzabicyclo[3.1.0]hex-6-yl-carbaMic Acid 1,1-DiMethylethyl Ester;tert-butyl N-[(1S,5R)-3-Azabicyclo[3.1.0]hexan-6-yl]carbaMate
• CAS NO: 134575-17-0
• Molecular Formula: C₁₀H₁₈N₂O₂
• Molecular Weight: 198.26212
• EINECS: 429-170-8
• Product Categories: N-BOC;PHARMACEUTICAL INTERMEDIATES;Amines;Chiral Reagents;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 134575-17-0.mol
• Article Data: 15

Chemical Properties

• Melting Point: 110-111°C
• Boiling Point: 305.331°C at 760 mmHg
• Flash Point: 138.46°C
• Appearance: white to off-white/
• Density: 1.116g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: -20?C Freezer
• Solubility: DMSO: >20mg/mL
• PKA: 12.39±0.20(Predicted)
• CAS DataBase Reference: Carbamic acid, 3-azabicyclo[3.1.0]hex-6-yl-, 1,1-dimethylethyl ester,(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, 3-azabicyclo[3.1.0]hex-6-yl-, 1,1-dimethylethyl ester,(134575-17-0)
• EPA Substance Registry System: Carbamic acid, 3-azabicyclo[3.1.0]hex-6-yl-, 1,1-dimethylethyl ester,(134575-17-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41-43-48/22
• Safety Statements: 22-26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 134575-17-0(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Pale Yellow Solid

Biochem/physiol Actions

CP-101537 is a MMP inhibitor, candidate drug for myocardial infarction therapy, and antibacterial.

InChI:InChI=1/C10H18N2O2/c1-10(2,3)14-9(13)12-8-6-4-11-5-7(6)8/h6-8,11H,4-5H2,1-3H3,(H,12,13)/t6-,7+,8?

Upstream product

• 146726-10-5 3-benzyl 6-ethyl (1α,5α,6α)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate 
• 174456-77-0 [(1α,5α,6α)-3-aza-bicyclo[3.1.0]hexane]-6-carboxylic acid ethyl ester 
• 151860-15-0 (1α,5α,6α)-3-N-benzyl-6-nitro-2,4-dioxo-3-azabicyclo[3.1.0]hexane 
• 151860-16-1 (1α,5α,6α)-3-N-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane 
• 151860-17-2 (1α,5α,6α)-3-N-benzyl-6-amino-3-aza-bicyclo[3.1.0]hexane 
• 134575-15-8 (1α,5α,6α)-3-(benzyloxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid 
• 134575-06-7 ethyl (1α,5α,6α)-3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylate 
• 134575-14-7 benzyl (1α,5α,6α)-6-hydroxymethyl-3-azabicyclo[3.1.0]hexan-3-ylcarboxylate 
• 134575-07-8 (1α,5α,6α)-6-hydroxymethyl-3-benzyl-3-aza-bicyclo[3.1.0]hexane 
• 134575-13-6 (1α,5α,6α)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane 
• 146726-08-1 (1α,5α,6α)-6-tert-butoxycarbonylamino-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid benzyl ester 
• 185559-52-8 (1α,5α,6α)-3-N-benzyl-6-[t-butoxycarbonylamino]-3-aza-bicyclo[3.1.0]hexane 

Downstream Products

• 256369-34-3 (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane ditosylate salt 
• 134575-66-9 7-([1α,5α,6α]-6-tert-Butoxycarbonylamino-3-azabicyclo[3.1.0]hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,ethyl ester 
• 925457-08-5 1-(2,4-difluorophenyl)-7-[(1α,5α,6α)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 392659-98-2 [(1α,5α,6α)-3-(2-fluoro-4-nitrophenyl)-3-azabicyclo[3.1.0]hex-6-yl]carbamic acid tert-butyl ester 
• 1003884-14-7 [(1α,5α,6α)-3-(4-chlorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl]carbamic acid tert-butyl ester 
• 1003884-20-5 [(1α,5α,6α)-3-(2-fluorobenzoyl)-3-azabicyclo[3.1.0]hex-6-yl]carbamic acid tert-butyl ester 
• 1003885-32-2 [(1α,5α,6α)-[3-(4-trifluoromethylphenylcarbamoyl)-3-azabicyclo[3.1.0]hex-6-yl]]carbamic acid tert-butyl ester 
• 392659-99-3 [(1S,5R,6S)-3-(2-Fluoro-4-nitro-phenyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-methyl-carbamic acid tert-butyl ester 
• 392660-00-3 [(1S,5R,6S)-3-(4-Amino-2-fluoro-phenyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-methyl-carbamic acid tert-butyl ester 
• 392659-54-0 N-[5(S)-3-[3-fluoro-4-[(1α,5α,6α)-6-(N-methyl)amino-3-azabicyclo[3.1.0]hexan-3-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide 
• 392660-02-5 {(1S,5R,6S)-3-[2-Fluoro-4-((R)-5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-3-aza-bicyclo[3.1.0]hex-6-yl}-methyl-carbamic acid tert-butyl ester 
• 392660-05-8 {(1S,5R,6S)-3-[4-((S)-5-Aminomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenyl]-3-aza-bicyclo[3.1.0]hex-6-yl}-methyl-carbamic acid tert-butyl ester 
• 392660-01-4 [(1S,5R,6S)-3-(4-Benzyloxycarbonylamino-2-fluoro-phenyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-methyl-carbamic acid tert-butyl ester 
• 392660-04-7 {(1S,5R,6S)-3-[4-((R)-5-Azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenyl]-3-aza-bicyclo[3.1.0]hex-6-yl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

Mechanisms of trovafloxacin hepatotoxicity: Studies of a model cyclopropylamine-containing system

The mechanism for the hepatotoxicity of trovafloxacin remains unresolved. Trovafloxacin contains a cyclopropylamine moiety which has a potential to be oxidized to reactive intermediate(s) although other putative elements may exist. In this study, a drug model of trovafloxacin containing the cyclopropylamine substructure was synthesized. Chemical oxidation of the drug model by K3Fe(CN)6 and NaClO revealed that both oxidants oxidize this drug model to a reactive α,β-unsaturated aldehyde, 11. The structure of 11 was fully elucidated by LC/MS/MS and NMR analysis. These results suggested that P450s with heme-iron center and myeloperoxidase generating hypochlorous acid in the presence of chloride ion are capable of bioactivating the cyclopropylamine moiety of trovafloxacin. This deleterious metabolism may lead to eventual hepatotoxicity.

INDOLE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS

Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salt thereof wherein R7, A, X, B, and n are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds

PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS

The present invention provides DNA Gyrase and/or Topo IV inhibitors of formula I, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonus spp., Acenetobacter spp., Muraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Mycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Cotyne bacterium, Bacillus spp., Enterobactericeae (E.coli, Klebsiella spp., Proteus spp.,etc.) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections